AU2018308649A1 - Compounds which specifically bind to CD38 for use in the treatment of neurodegenerative and inflammatory diseases - Google Patents

Compounds which specifically bind to CD38 for use in the treatment of neurodegenerative and inflammatory diseases Download PDF

Info

Publication number
AU2018308649A1
AU2018308649A1 AU2018308649A AU2018308649A AU2018308649A1 AU 2018308649 A1 AU2018308649 A1 AU 2018308649A1 AU 2018308649 A AU2018308649 A AU 2018308649A AU 2018308649 A AU2018308649 A AU 2018308649A AU 2018308649 A1 AU2018308649 A1 AU 2018308649A1
Authority
AU
Australia
Prior art keywords
compound
disease
antibody
naadp
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2018308649A
Other languages
English (en)
Inventor
Laurence Bressac
Serge GUERREIRO DA SILVA
Damien Toulorge
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Encefa
Original Assignee
Encefa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Encefa filed Critical Encefa
Publication of AU2018308649A1 publication Critical patent/AU2018308649A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2018308649A 2017-07-24 2018-07-24 Compounds which specifically bind to CD38 for use in the treatment of neurodegenerative and inflammatory diseases Abandoned AU2018308649A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17315006.1 2017-07-24
EP17315006.1A EP3434692A1 (en) 2017-07-24 2017-07-24 Compounds which specifically binds to cd38 for use in the treatment of neurodegenerative diseases
PCT/EP2018/070064 WO2019020643A1 (en) 2017-07-24 2018-07-24 COMPOUND BINDING SPECIFICALLY TO CD38 FOR USE IN THE TREATMENT OF NEURODEGENERATIVE AND INFLAMMATORY DISEASES

Publications (1)

Publication Number Publication Date
AU2018308649A1 true AU2018308649A1 (en) 2020-02-13

Family

ID=59626538

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018308649A Abandoned AU2018308649A1 (en) 2017-07-24 2018-07-24 Compounds which specifically bind to CD38 for use in the treatment of neurodegenerative and inflammatory diseases

Country Status (7)

Country Link
US (1) US20210087290A1 (https=)
EP (2) EP3434692A1 (https=)
JP (2) JP2020528447A (https=)
CN (1) CN111108127A (https=)
AU (1) AU2018308649A1 (https=)
CA (1) CA3070756A1 (https=)
WO (1) WO2019020643A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200345725A1 (en) 2019-01-11 2020-11-05 Omeros Corporation Methods and Compositions for Treating Cancer
WO2021021986A1 (en) 2019-07-31 2021-02-04 Ribon Therapeutics, Inc. Heterobicyclic amides as inhibitors of cd38
EP4054714A4 (en) * 2019-11-07 2023-12-06 Ohio State Innovation Foundation METHODS AND COMPOSITIONS FOR SELECTIVE INTRACELLULAR DELIVERY OF CD38 INHIBITORS
EP3943505A1 (en) * 2020-07-22 2022-01-26 Encefa Cd38-binding cd31 peptides and uses thereof
WO2022152823A1 (en) 2021-01-14 2022-07-21 Morphosys Ag Anti-cd38 antibodies and their uses
HRP20251111T1 (hr) 2021-01-29 2025-11-21 Boehringer Ingelheim International Gmbh Azakinolini kao inhibitori cd38
TW202302642A (zh) 2021-03-01 2023-01-16 德商莫菲西斯公司 用於治療抗體介導移植物排斥用途之抗ｃｄ３８抗體
WO2024090500A1 (ja) 2022-10-28 2024-05-02 日本精工株式会社 回転支持装置、及び軸支持装置の支持機構位置調整機構
WO2026075985A1 (en) * 2024-10-01 2026-04-09 Neolaia Inc. Quinoline- and quinazoline-carboxamide derivatives as cd38 inhibitors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
EP1914242A1 (en) * 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
ATE542830T1 (de) 2006-12-04 2012-02-15 Pasteur Institut Als gerüst verwendeter ob-fold zur entwicklung neuer spezifischer bindemittel
DK2580243T3 (da) * 2010-06-09 2020-01-13 Genmab As Antibodies against human cd38
JOP20210044A1 (ar) * 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
US20120328526A1 (en) 2011-06-27 2012-12-27 University Of Maryland, Baltimore Modulation of Nad+ Activity in Neuropathophysiological Conditions and Uses Thereof
US20150093399A1 (en) 2013-08-28 2015-04-02 Bioasis Technologies, Inc. Cns-targeted conjugates having modified fc regions and methods of use thereof
WO2016024246A1 (en) 2014-08-14 2016-02-18 Universita' Degli Studi Di Roma 'la Sapienza' A therapeutic use of naadp and/or tcp2 antagonists
MX386886B (es) * 2014-09-09 2025-03-12 Janssen Biotech Inc Combinación de anticuerpos anti-cd38 y ácido todo-trans retinoico para usarse en terapias.
TWI769982B (zh) 2015-06-24 2022-07-11 日商Ｊｃｒ製藥股份有限公司 通過血腦障壁之抗人類運鐵蛋白受體抗體
HRP20240338T1 (hr) * 2015-06-24 2024-05-24 Janssen Biotech, Inc. Imunomodulacija i liječenje solidnih tumora s protutijelima koja se specifično vežu na cd38
WO2017096246A1 (en) * 2015-12-03 2017-06-08 Temple University-Of The Commonwealth System Of Higher Education Modulation of nad+ and nad+ metabolic pathways for treatment of disease

Also Published As

Publication number Publication date
EP3434692A1 (en) 2019-01-30
EP3658586A1 (en) 2020-06-03
CN111108127A (zh) 2020-05-05
CA3070756A1 (en) 2019-01-31
JP2023134636A (ja) 2023-09-27
JP2020528447A (ja) 2020-09-24
US20210087290A1 (en) 2021-03-25
WO2019020643A1 (en) 2019-01-31

Similar Documents

Publication Publication Date Title
US20210087290A1 (en) Compounds which specifically bind to cd38 for use in the treatment of neurodegenerative and inflammatory diseases
JP7398396B2 (ja) Ｂｃｍａに対する結合分子及びその使用
JP7489407B2 (ja) Ｃｄ１９結合分子及びその使用
TWI573805B (zh) 抗轉鐵蛋白受體抗體及其使用方法
CN104955838B (zh) 双特异性EGFR/c-Met抗体
TW201625683A (zh) 抗介白素－３３抗體及其用途
CN107001473A (zh) 抗‑运铁蛋白受体抗体及使用方法
KR20220010743A (ko) Bcma에 대한 삼중특이적 결합 분자 및 이의 용도
CN102906117A (zh) 抗lrp6抗体
WO2016094566A2 (en) Blood brain barrier receptor antibodies and methods of use
US20180222974A1 (en) Compositions and methods for using anti-il-34 antibodies to treat neurological diseases
TW202225191A (zh) 抗ｃｄ２０／抗ｃｄ３雙特異性抗體之皮下給藥
CN114269375A (zh) 抗cd38抗体和配制品
RU2829901C2 (ru) Триспецифические молекулы, связывающие bcma, и пути их применения
TW202600596A (zh) 抗ＦＧＦＲ２ｂ抗體、其抗體藥物偶聯物及其用途
HK40105342A (zh) 针对用抗cd20/抗cd3双特异性抗体和抗cd79b抗体药物缀合物进行组合治疗的给药
EA048268B1 (ru) Молекулы, связывающие bcma, и пути их применения
HK1243440B (zh) 抗白细胞介素-33抗体及其用途

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application